Page 1

Exhibit 99.1 Galapagos reports commercial and operational progress at Q3 financial results First nine months 2021 financial results : Galápagos • Group revenues of € 317.9 million • Operating loss of € 175.7 million • Net loss of € 119.6 million • Cash and current financial investments of € 4.9 billion on 30 September 2021 Filgotinib launch in RA on track with reimbursement secured in 14 countries Reduced 2021 cash burn guidance by € 50 million to € 530- € 570 million Webcast presentation tomorrow , 5 November 2021 , at 13.00 CET / 8 AM ET , www.g ! pg.com , +32 2 793 38 47 , code 4987105 Mechelen , Belgium ; 4 November 2021 , 22.01 CET ; regulated information - Galapagos NV ( Euronext & NASDAQ : GLPG ) is pleased to report on its commercial launch of filgotinib in Europe . The company is moving forward with its revised R & D strategy and operational restructuring announced in May , resulting in a downward adjustment of the cash burn by € 50 million . The unaudited Q3 financial and operational results are further detailed in the Q3 2021 report available on the website , www.g ! pg.com . " This quarter we achieved key steps in our growing commercial business in Europe , while moving earlier - stage R & D programs forward . We continue to deliver on our revised strategy , accelerating the savings program announced at the first quarter results . We are focused on nominating a successor to lead our company going forward following my eventual retirement as CEO , ” said Onno van de Stolpe , CEO of Galapagos . “ Supported by our strong balance sheet and long - term R & D collaboration with Gilead , we believe that Galapagos remains well - positioned for future growth . " " After years of hard work by so many , we are very excited to bring Jyseleca to market as a new treatment option for people living with rheumatoid arthritis ( RA ) . As per 30 September 2021 , we booked € 6.1 million in net sales for Jyseleca , for a total of € 15.8 million together with Gilead . Encouraged by these sales of our first commercial product and its positioning in the growing JAK market in Europe , we are confident in the commercial potential of our Jyseleca franchise in Europe . Following the positive CHMP opinion for filgotinib for the treatment of patients with ulcerative colitis ( UC ) , we expect a decision by the European Commission ( EC ) before year - end , and if granted , we are ready to go full steam ahead with the commercial roll - out in a second indication , ” added Bart Filius , President and COO of Galapagos . " Following our strategic operational review in March 2021 , we implemented a cost savings program of € 150 million on a full year basis . As a result of an acceleration of this program , we revise our guidance for full year 2021 operational cash burni from € 580 to € 620 million to € 530 to € 570 million . " 1